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CHAPTER 1: GENERAL INTRODUCTION AND LITERATURE REVIEW 
General Introduction 
Shiga toxin (Stx)-producing Escherichia coli (STEC) cause disease in humans and 
pigs. The pathogenesis of STEC disease depends on the production of a number of 
different virulence factors by the bacteria, including Stxs. All STEC strains produce one or 
more Stx types (Stx 1, Stx2), important virulence factors that mediate systemic STEC 
disease. Stxs are cytotoxic for vascular endothelial (34, 58, 65, 86, 104, 105, 137) and renal 
epithelial cells (54, 55, 77, 79) and cause lesions in the kidney, colon, and central nervous 
system (110). Human monocytes (116, 150) and polymorphonuclear leukocytes (PMN) 
(132, 133) also bind Stxs, but there is limited information regarding the roles these 
leukocytes may play in Stx-mediated damage. The mechanisms of Stx-mediated damage 
remain to be fully elucidated. 
The identification of tissues and cell types to which Stxs bind will facilitate 
elucidation of the mechanisms of Stx-mediated tissue damage. In this thesis, we used 
tissues isolated from pigs, a natural host for systemic STEC disease, to identify Stx binding 
sites. The objectives of the first study in this thesis were to (i) identify Stxl and Stx2 
binding sites in multiple porcine tissues and (ii) determine if Stxs bind to isolated porcine 
leukocytes. An immunohistochemical Stx overlay assay that was previously used for the 
identification of Stx binding sites in bovine tissues ( 114) was modified for use with porcine 
tissues and leukocytes. Stx binding sites were identified in all tissue types tested (i.e., 
kidney, brain, intestine, and liver obtained from neonatal pigs), and we demonstrated Stx 
binding to fixed porcine alveolar macrophages and peripheral blood monocytes and PMN. 
In the second study in this thesis, a flow cytometric assay to monitor Stx binding to isolated 
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porcine peripheral blood PMN was developed. Stx2 was used as a representative Stx type. 
The resulting assay is amenable for use in functional studies with isolated porcine PMN. 
Thesis Organization 
This thesis consists of three chapters followed by a general conclusions and 
summary section. Chapter 1 contains a literature review that provides a discussion of the 
Stx types, Stx cytotoxicity, and what is known about Stx binding sites in mammalian 
tissues. Chapter 2 is a paper published in Infection and Immunity that covers the 
identification of Stx binding sites in porcine tissues and fixed leukocytes. Chapter 2 was 
modified to meet the thesis requirements of Iowa State University and differences in format 
can be observed between Chapter 2 and the published version. A reprint is included in the 
appendix for further reference. Chapter 3 describes the development of a flow cytometric 
assay to measure Stx2 binding to isolated porcine peripheral blood PMN. References are 
cited at the end of each chapter. 
Literature Review 
Introduction 
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Shiga toxin (Stx)-producing Escherichia coli (STEC), including serotype E. coli 
O157:H7 strains, cause diarrhea and hemorrhagic colitis [reviewed in (67, 138)] in humans. 
An estimated 70,000 STEC infections occur each year in the United States (92). The illness 
may progress to systemic disease that includes the hemolytic uremic syndrome (HUS) and 
central nervous system (CNS) complications (67, 138). HUS is a potentially fatal condition 
that includes thrombocytopenia, acute renal failure, and microangiopathic hemolytic 
anemia (67, 113). 
All STEC strains characteristically produce one or more Shiga toxin (Stxs), 
important virulence factors in the development of systemic STEC disease [ reviewed in (81, 
101)]. There are two main Stx types produced by STEC, Stxl and Stx2. At least one Stxl 
variant (10) and several Stx2 variants (110) have been identified. Stxs are potent cytotoxins 
that recognize a membrane receptor called globotriaosylceramide (Gb3; also known as 
CD77) on target cells ( 101) and mediate lesions in the intestine, kidney and central nervous 
system (67, 81 , 138). One Stx2 variant, Stx2e, which is produced by STEC strains that 
cause porcine edema disease (89, 95), preferentially recognizes a related receptor called 
globotetraosyl ceramide (Gb4) (23). 
Shiga toxins 
Structure and activity 
Stxl and Stx2 types (previously known as Shiga-like toxin 1 and Shiga-like toxin 2) 
are so named because they are structurally similar to and possess the same activity as Stx 
produced by Shigella dysenteriae type 1. All Stxs have an AB5 holotoxin structure 
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consisting of a single A subunit that mediates enzymatic activity and a pentamer of 
identical B subunits that confers binding to receptors. The toxic activity of Stxs are 
identical to that of the plant toxin ricin (33). Following internalization into sensitive cells, 
the A subunits of Stxs and ricin are proteolytically nicked into an active fragment that has 
N-glycosidase activity on rRNA and causes inhibition of protein synthesis (32, 33). 
Stxl shares nearly identical amino acid homology to Stx, differing by only one 
amino acid [reviewed in (48, 101)]. Stx2 shares 56% amino acid homology with Stxl, and 
about 90% homology with Stx2e (160). Stx2 is antigenically distinct from both Stxl and 
Stx ( 48, 101 ). Stx 1, but not Stx2, can be neutralized by antiserum directed against Stx 
(103, 129). There are also genetic differences between Stx types. The stx:1 and stx:2 genes in 
STEC strains are encoded on temperate bacteriophages ( 48, 101 ). In contrast, the stx gene 
from S. dysenteriae type 1 is chromosomally-encoded (102). The stx:2e gene is also believed 
to be chromosomally-encoded (89, 93, 160), but at least one stx2e-encoding bacteriophage 
has been reported (96). 
Stxl and Stx2 differ in binding affinities and toxicity. Stxl has a higher affinity for 
Gb3 than does Stx2 ( 49, 51, 65, 13 5), but Stx2 dissociates from Gb3 at a slower rate than 
Stxl (49, 99). Stx2 is toxic to isolated vascular endothelial cells at lower doses than Stxl 
(65, 86, 106). The lethal dose of Stx2 is lower than that of Stxl when administered 
intravenously to pigs (42) and mice (135). In baboons, Siegler, et. al., (125) showed that 
animals injected intravenously with Stx2 develop HUS symptoms, but those receiving Stxl 
do not. Human epidemiological (7, 78, 122) and animal experimental data (26, 80, 153) 
indicate that infections with Stx2-producing strains are associated with the development of 
more severe disease than infections with strains that produce Stx 1 only or both Stx 1 and 
Stx2. 
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The differences in binding and the relative cytotoxicities of Stx types may be due, in 
part, to differences in Stx B subunit composition and the nature of Gb3. Several studies 
with hybrid toxins (49, 120, 159) demonstrated that the specific localization and activity of 
Stx types are associated with the B subunits. In one such study, Head, et. al, (49) 
demonstrated that a Stx1A:Stx2B hybrid had the same cytotoxic activity as Stx2 holotoxin 
and a Stx2A:Stx1B hybrid toxin had the same cytotoxic activity as Stxl holotoxin in Vero 
and MRC-5 cell cytotoxicity assays. The sensitivity of target cells also corresponds to Gb3 
density (105, 106, 137) and the nature of the Gb3 isoforms (84, 111). A number of studies 
by Lingwood and colleagues demonstrate that the fatty acid content of Gb3 affects the 
affinity of Stx binding, that Gb3 isoforms differentially bind Stx 1 and Stx2 and that not all 
Gb3 are Stx receptors (13, 75, 84, 111). 
Purification 
The culture conditions required for Stx purification differ based on the Stx type to 
be purified. Stx production by S. dysenteriae and Stxl by STEC strains is regulated by iron 
concentration in the culture medium and is induced under low iron conditions (103, 158), 
but can be further augmented in the presence of phage-inducing agents (50, 91, 156, 158). 
In contrast, Stx2 and Stx2e production are not affected by iron levels, but are induced by 
the use ofrich media (42, 87, 160) or in the presence of phage-inducing agents (46, 50, 98, 
155). Stxs are cell associated and can be released from bacterial cells by mechanical lysis 
( e.g., French press extraction or sonication). In some purification protocols, crude bacterial 
lysates are first fractionated by the use of an ammonium sulfate precipitation step (25, 27, 
87, 100, 165). Purification of Stxs from crude Stx bacterial lysates or ammonium sulfate 
precipitated fractions is accomplished by chromatography (25, 27, 87, 100, 165). Although 
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crude Stx bacterial lysates have been used as Stx preparations for some Stx binding and 
toxicity studies (82, 114, 120), purified Stxs have been used for most studies. 
Role of Stxs in STEC disease 
In vitro models 
A number of isolated human cell types have been used to study the mechanisms of 
Stx-mediated cell damage. Stxs are cytotoxic for isolated vascular endothelial (34, 58, 65, 
86, 104, 105, 137), renal tubular epithelial (54, 55, 77, 79), renal glomerular (54, 56, 161) 
and intestinal epithelial cells (52, 121). These findings are consistent with histopathological 
reports of vascular and epithelial cell damage in the colon and kidney and vascular damage 
in the central nervous system of patients with systemic STEC disease [reviewed in (110, 
113)]. Other Stx-sensitive cell lines used in Stx studies include human Burkitt's lymphoma 
cells (15), MRC-5 lung fibroblasts (49), Hep-2 laryngeal carcinoma cells (43) and Vero 
cells (an African green monkey kidney cell line) (43). 
In vitro studies have provided evidence that Stx may also mediate damage through 
indirect mechanisms. One possible mechanism is Stx-mediated upregulation of 
proinflammatory mediators. Stxs induce cytokine expression (i.e., TNF-a, IL-lp, IL-6) by 
isolated human vascular endothelial cells (30, 128) and peripheral blood monocytes (116, 
150) and CXC chemokine expression by epithelial cells (139, 164). Both TNF-a and IL-lP 
increase vascular endothelial cell sensitivity to Stxs through upregulation of Gb3 (31, 70, 
115, 146, 147). Stx-induced expression of CXC chemokines mediate adhesion and 
migration of inflammatory cells, such as polymorphonuclear leukocytes (PMN) (1, 24, 37, 
140, 166), to sites of tissue damage. 
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Several lines of evidence indicate that host leukocytes play a role in Stx-mediated 
tissue damage. Isolated human peripheral blood monocytes bind Stx and Stx binding 
induces proinflammatory cytokine expression (115 , 150). Monocytes are proposed to be a 
key source of elevated levels of TNF-a, IL-1 p, and IL-6 detected in the plasma and urine 
from some HUS patients (62, 97, 148). In mouse studies, isolated murine monocytes and 
macrophages also bind Stx and produce TNF-a, IL-lp, and IL-6 (2, 136). In vivo studies 
with mice showed that elevated levels of these cytokines enhance Stx toxicity (2, 108). 
Palermo, et. al. , (108) demonstrated that splenic and hepatic macrophages are important for 
Stx toxicity in mice. Depletion of splenic and hepatic macrophages enhanced the survival 
of mice that were administered Stx2 (108). 
PMN are also likely involved in STEC disease. In HUS patients, high levels of 
circulating PMN are associated with a poor disease outcome (37, 157). The expression of 
the CXC chemokine IL-8, a potent PMN chemoattractant, by renal and intestinal epithelial 
cells (139, 164) may localize PMN to tissue sites where Stx-mediated damage is observed. 
This is consistent with the presence of PMN in the kidney (61 , 149) and colon (72) of HUS 
patients and of similar PMN infiltration in the intestinal mucosa of experimentally STEC-
infected calves (20, 127), pigs ( 4 7) and rabbits (107). Migration of PMN into these sites 
may be further promoted by Stx-mediated upregulation of adhesion molecules (35, 166) on 
PMN. Peripheral blood PMN obtained from HUS patients are activated and readily 
adherent to endothelium (37). In mice, Stx administration upregulates the expression of 
CD 11 b, an adhesion molecule that promotes PMN adherence to endothelium (3 5). 
Following migration of PMN into various sites, IL-8 induced activation of PMN may 
contribute to tissue damage through release of proteases and superoxides from PMN 
cytoplasmic granules (36, 37, 166). 
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Experimental studies with human PMN indicate that PMN may play additional roles 
in Stx-mediated damage. One potential mechanism is through Stx-mediated modulation of 
PMN functions. Stx binds to human PMN in vitro and in vivo (132). Stx binding to human 
PMN delays apoptosis (85), suppresses phagocytosis and PMN response to stimulants (76), 
and upregulates the oxidative burst (76). Such modulation of PMN functions may delay 
clearance of STEC or other pathogens and enhance the release of tissue-damaging 
superoxides and proteases from PMN (36, 37, 76). Another potential mechanism is PMN-
mediated transport of Stx. Hurley, et. al., (57) showed that migration of PMN across 
polarized epithelial cells facilitates passive Stx movement of Stx across cell layers. In 
another study, human PMN with bound Stx were found to transfer Stx to endothelial cells 
in vitro (132). 
Stxs can also bind to other blood components, including isolated human (6) and 
porcine (90) red blood cells and human platelets ( 16, 44, 68). The effect of Stx binding to 
red blood cells is unknown. Studies with isolated human platelets show that Stx binding to 
platelets induces platelet aggregation (68), which may be involved in the development of 
thrombocytopenia in HUS patients. 
In vivo models 
A number of animal models are in place to evaluate Stx-mediated damage. Rabbit 
and mouse models, which were used to study S. dysenteriae disease pathogenesis and Stx 
(29, 73, 91), are also used to study STEC disease and Stx-mediated damage (3, 4, 41, 69, 
71, 80, 107, 124, 154). Other models, including calves (18, 21), ferrets (163), baboons 
(130), and pigs (47), are also used to study various features of STEC disease (17, 22, 28, 
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38, 42, 88, 142). Although no single animal model completely reproduces all aspects of 
human STEC disease, several aspects of human STEC disease can be reproduced in pigs. 
Pigs have several features that make them an ideal model to study STEC disease and 
Stx-mediated damage. Pigs are susceptible to both natural infection with STEC strains that 
cause edema disease (17, 89, 95) and to experimental infection with human STEC strains 
(19, 19, 22, 38, 47, 141-143). Pigs experimentally infected with human STEC strains (19, 
19, 22, 47, 112, 141) or those administered Stx intramuscularly (28) or intravenously (9, 
42) develop renal and CNS lesions that are similar to lesions observed in humans with 
systemic STEC disease. The results of a study by Chrisopher-Hennings, et. al. , (14) 
suggest that Stxs may have immunomodulatory effects on pigs. Experimental infection of 
gnotobiotic pigs with an STEC O 111 :NM strain that produces Stx 1, but not with a Stx-
negative O 111 :NM strain, suppresses peripheral blood lymphocyte counts and lymphocyte 
response to mitogen stimulation (14). 
Localization of Stx binding sites 
The localization of Stx binding sites will facilitate the elucidation of mechanisms of 
Stx-mediated damage site by identifying which cell types and tissues to study further. Such 
studies may also be useful for determining if there are any differences between Stx 1 and 
Stx2 binding that may account for the increased virulence associated with Stx2. Little is 
known about the localization of Stx 1 and Stx2 binding sites in most species studied. 
Several studies were completed with human kidneys (8, 12, 83 , 134, 144). The most 
extensive evaluations of Stx binding sites have been in bovine tissues (53 , 114) and, to a 
lesser extent, in murine tissues (59, 60, 119). These studies show that Stx binds to 
epithelial cells and within lymphoid aggregates in the intestine (53) and tubules in the 
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kidney (53, 114) in cattle. In mice, Stx binds to epithelial cells in the colon (60), tubules in 
the kidney (59, 119), neurons in the CNS (117) and capillaries and pneumocytes in lung 
alveoli (119). 
Porcine tissues are ideal for Stx binding studies. As noted earlier, pigs develop Stx-
mediated lesions that are similar to lesions observed in humans with systemic STEC disease 
(22, 47, 112, 141). Pig tissues contain Gb3 (9, 47) and the localization of intravenously 
administered Stx corresponds to the gross distribution of Gb3 in tissues (9). There is 
limited information regarding the localization of Stx binding sites within porcine tissues. 
Waddell, et. al., (152) reported the identification of Stx2e binding sites in multiple porcine 
tissues. However, because Stx2e preferentially recognizes Gb4 as a receptor (23, 74), the 
Stx2e binding sites identified in that study might not reflect binding sites for Stxs that 
preferentially recognize Gb3. Gunzer, et. al., (47) demonstrated that Stx2 binds to vascular 
tissue in porcine CNS, kidney and colon and Pruimboom-Brees, et. al., (114) reported that 
Stxs bind to vascular tissue in porcine ileum. The findings that Stxs bind to mononuclear 
cells in porcine ileal lamina propria (114) and to fixed isolated porcine alveolar 
macrophages (162) (described in Chapter 2 of this thesis) and to peripheral blood 
monocytes and PMN indicate that porcine leukocytes contain Stx binding sites. 
Various methods to identify Stx binding sites in tissues have been described, and 
each method has its limitations. One method is to identify histological lesions in animals 
that are infected with Stx-producing E.coli strains (19, 22, 39, 47, 63, 82) or in animals that 
receive parenterally administered crude (42) or purified Stx (3, 40, 88, 107, 118, 123, 130, 
167). From such studies it is difficult to determine if a lesion is the direct result of Stx 
binding at the lesion site or if the lesion is an indirect result of Stx binding to another site. 
Another method is to measure the distribution ofradio-labeled Stx that is parenterally 
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administered into test animals (5, 9, 118, 119). Injection ofradio-labeled Stx can be useful 
for the identification of organs into which Stx localizes in vivo, but such studies provide 
limited information regarding the specific localization of Stx binding sites within organs. 
A third method to identify Stx binding sites requires the use of tissue sections. 
Prepared tissue sections are incubated with fluorescein isothiocyanate (FITC)-labeled Stx 
(83) or analyzed in Stx overlay immunoassays (12, 41, 47, 53, 59, 60, 66, 80, 114, 117-119, 
134, 135, 144, 152). The identification of Stx binding sites in tissues by overlay 
immunoassays generally involves sequential incubations of samples in crude or purified Stx 
(or B subunits), a primary antibody directed against Stx and a labeled secondary antibody. 
In some studies, a secondary antibody labeled with FITC was used and Stx binding was 
identified by using fluorescence microscopy (59, 117, 118, 134, 135, 145). In other studies, 
a secondary antibody labeled with peroxidase (60, 66, 80) or biotin (41, 47, 53, 114, 119) 
was used along with appropriate colorimetric detection reagents. Stx binding was identified 
by using light microscopy. For in situ detection of Stx binding in tissue sections, the 
incubation with Stx or Stx B subunits is omitted (12, 118, 144). The use ofFITC-labeled 
Stx ( or B subunits) or Stx overlay immunoassays provides more information regarding the 
structures or cell types within organs to which Stxs bind than does the administration of 
radio-labeled Stx. It is possible that not all Stx binding sites identified by in vitro assays are 
in vivo Stx binding sites. 
A more indirect approach to identifying Stx binding sites is through the localization 
ofGb3 distribution (8, 9, 47, 53, 60, 114, 119, 134, 135, 144, 145, 167). Gb3 can be 
assessed by isolation of glycolipids from various tissues, separating the glycolipids on thin 
layer chromatography plates, and detection of Gb3 by overlay assays (8, 9, 47, 117, 120, 
134). Isolated Gb3 can be quantitatively assessed by HPLC (8, 9). Gb3 distribution is also 
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assessed by sequential incubation of tissue sections in anti-CD77 antibodies, an appropriate 
labeled secondary antibody, and colorimetric detection reagents (47, 109, 144) or in anti-
CD77 antibodies and a FITC-labeled secondary antibody (134, 135, 145). The detection of 
Gb3 within an organ or tissue section may or may not reflect the presence of Stx binding 
sites because Stx binding is dependent on the Gb3 isoform (13 , 75 , 84, 111). 
Stx binding to isolated cells has been reported in a number of studies. Stx binding 
to human peripheral blood platelets (151) and monocytes (150) has been assessed by 
incubation of cells in radio-labeled Stx, although the use of fluorophore-labeled reagents is 
reported for most studies. Similar to studies with tissue sections, isolated cells can be 
incubated in fluorophore-labeled Stx or Stx B subunits (6, 16, 44, 126, 132) or sequentially 
incubated in Stx or Stx B subunits, anti-Stx antibodies and fluorophore-labeled secondary 
antibodies (68, 90, 94, 116, 126, 131). Stx binding is identified by fluorescence microscopy 
or flow cytometry. Such fluorescence assays have been used to demonstrate Stx binding to 
human peripheral blood erythrocytes (6), platelets (16, 44, 68), monocytes (116), and PMN 
(131-133), to bovine lymphocytes (94, 126) and to porcine erythrocytes (90). 
A key advantage of fluorescence assays over radioactivity-based assays to study Stx 
binding to isolated cells is the ability to simultaneously measure more than one parameter 
on each cell (e. g ., identification of Stx binding and the presence of a cell marker). 
Fluorescence microscopy is generally limited to two fluorescence signals and may require 
several minutes to hours for a microscopist to evaluate several hundred cells on prepared 
slides. In comparison, flow cytometers are equipped with one or more lasers and an array 
of filters and photodetectors that allow simultaneous detection of cell size and complexity 
and up to six different fluorescent signals per cell. A high number of cells ( e.g., 1000-
10,000 per sample) can be analyzed within several seconds. Flow cytometric assays have 
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been used to characterize the binding of several bacterial toxins to target cells, including 
endotoxin (11), cholera toxin (64) and adenylate cyclase toxin (45). Flow cytometric 
assays will be a useful means for continued study of Stx binding to isolated cells. 
Conclusions 
The pathogenesis of Stx-mediated disease is not fully understood. Porcine models 
are useful for studying Stx-mediated disease and will be ideal for Stx binding studies due to 
the susceptibility of pigs to Stx-mediated tissue damage and the presence of Gb3 in porcine 
tissues. The identification of Stx binding sites will facilitate the identification of the 
mechanisms of Stx-mediated damage. A number of techniques are available to study Stx 
binding and each technique has its limitations. The use of more than one technique to 
identify Stx binding sites will help overcome the limitations of any single method. For 
porcine Stx binding studies, the use of Stx overlay assays in parallel with anti-CD77 assays 
(to detect Gb3) will be useful for the identification of Stx binding sites in tissues. 
Fluorescence assays with microscopic or flow cytometric detection ( or both) will be useful 
for determining if porcine leukocytes contain Stx binding sites and Gb3. 
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CHAPTER 2: SHIGA TOXIN BINDING TO ISOLATED PORCINE 
TISSUES AND PERIPHERAL BLOOD LEUKOCYTES 
A paper published in Infection and Immunity. 
Kellie R. K. Winter, 1 William C. Stoffregen,2 and Evelyn A. Dean-Nystrom3'4 
Abstract 
Shiga toxin (Stx) binding sites in porcine tissues and leukocytes were identified by 
the use of Stx overlay and anti-CD77 /Gb3 immunoassays. Stx 1 and Stx2 bound to similar 
tissue locations and leukocytes, although some differences were noted. Previously 
unreported Stx binding sites were identified in kidney tubules, intestinal lymphoid 
aggregates, sinusoidal liver cells, alveolar macrophages, and peripheral blood leukocytes. 
Study Report 
Shiga toxin (Stx)-producing Escherichia coli (STEC) strains, including STEC 
O157:H7, cause diarrhea, hemorrhagic colitis, and hemolytic-uremic syndrome in humans 
(26). All STEC strains produce one or more Shiga toxins (Stxl or Stx2) which mediate 
damage in the kidney, colon, and brain (26). All Stx types can bind to glycolipid receptors 
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called globotriaosylceramides (Gb3) (26). Stx2-producing strains are more frequently 
associated with severe disease than are strains that produce only Stxl or both Stxl and Stx2 
(2, 8). The mechanisms of Stx-mediated tissue damage are not fully understood. 
A primary mechanism of Stx-mediated damage is direct Stx cytotoxicity for vascular 
endothelial (9, 24) and renal epithelial (16) cells. Proposed indirect mechanisms include Stx-
induced vascular damage and ischemia (26), Stx-induced immunomodulation (5), Stx-
induced activation of platelets (17), and Stx transport by leukocytes (32, 34). Several lines 
of evidence indicate that leukocytes are involved in Stx-mediated damage. Stxl binds to 
isolated human (28, 32, 34) and bovine (30) leukocytes, and Stx binding suppresses the 
activation and proliferation oflymphocytes from some cattle (10, 20) and induces the 
production of proinflammatory mediators by human monocytes (28, 34). These mediators 
may contribute to endothelial cell damage by inducing the localization and activation of 
polymorphonuclear cells (PMN) (11) or by sensitizing endothelial cells to Stx cytotoxicity 
(31 ). Stx also binds to isolated human PMN, which may deliver Stx to target cells (32). 
The identification of Stx binding sites is a key step toward elucidating the 
mechanisms of Stx-induced damage. Pigs are an ideal model for Stx binding studies because 
they are susceptible to natural (23) and experimental (12, 18, 33) Stx-mediated disease and 
develop typical Stx-mediated vascular lesions (6, 7, 14, 33). Pig tissues contain Gb3 and 
bind Stx (3, 14) and Stx binding correlates with gross tissue levels of Gb3 (3 ). 
Information about the locations of Stx binding sites in porcine tissues is limited 
mostly to vascular and endothelial sites (14, 27). The only direct comparison of Stxl and 
Stx2 binding to porcine tissues was done with ileal tissues (27). Stx binding to mononuclear 
cells in the ileal lamina propria (27), Stx toxicity for alveolar macrophages (21) and STEC-
induced changes in lymphoid tissue in gnotobiotic pigs (5) provide indirect evidence that Stx 
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also binds to porcine leukocytes. The objectives of this study were to (i) identify Stxl and 
Stx2 binding sites in porcine tissues and (ii) determine if Stx binds to porcine leukocytes. 
Stx binding sites and Gb3 were identified by immunoassays with frozen tissues 
(kidney, ileum, cerebellum, liver, spiral colon, and cecum from three pigs and jejunum from 
two pigs) obtained from <4-day-old cesarean section-derived, colostrum-deprived or 
naturally farrowed, colostrum-fed pigs. These tissues were available from pigs used for other 
studies at the National Animal Disease Center (NADC), Ames, Iowa. None of the pigs had 
been infected with Stx-producing E. coli. Frozen tissue sections were cut and fixed in 
undiluted acetone and then cryopreserved (27). 
Stxl and Stx2 binding sites in frozen porcine tissues were identified by use of an Stx 
overlay assay (27) which was modified for porcine tissues as noted below. Tissue sections 
were sequentially incubated with affinity-purified Stxl or Stx2 (provided by Alison O'Brien, 
Uniformed Services University of the Health Sciences, Bethesda, Md.) diluted to 3.5 and 3.0 
µg/ml, respectively, with monoclonal (anti-Stxl Mab13C4 or anti-Stx2 Mabl lEl0) 
(provided by James Samuel, Texas A&M University, College Station, Tex.) or polyclonal 
rabbit anti-Stx2 (Alison O'Brien) antibodies diluted in normal goat serum (Kirkegaard & 
Perry Laboratories [KPL ], Gaithersburg, Md.), and with biotin-streptavidin-alkaline 
phosphatase detection reagents. The following modifications were incorporated: (i) Tris-
buffered saline (TBS; 0.1 M Tris, 120 mM NaCl, pH 7.6) was used instead of 0.1 M Tris, (ii) 
hybridization covers (Grace Bio-Labs, Bend, Oreg.) were used for all incubations, except for 
those with the substrate, and (iii) biotinylated reagents were supplemented with normal swine 
serum (NSS; in-house reagent; used at a 10% [ vol/vol] final concentration). Stx2 binding 
was also assayed by use of a 10-fold higher concentration of Stx2 (30 µg/ml) and polyclonal 
anti-Stx2. Negative control sections were incubated with TBS instead of Stx or with 
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heterologous primary antibodies. Bound Stx appeared as a red precipitate against the blue 
counterstained background. 
The distribution of Gb3 in frozen porcine tissues was determined by immunostaining 
with anti-CD77/Gb3 (14). Tissue sections were sequentially incubated (1 hat 37°C) with rat 
monoclonal anti-CD77/Gb3 (diluted 1:10 in TBS) (Accurate Chemical, Westbury, N.Y.), 
biotinylated goat anti-rat immunoglobulin M (IgM; diluted 1 :200 in TBS with 10% [ vol/vol] 
NSS) (KPL), alkaline phosphatase conjugate (KPL), and HistoMark Red substrate (KPL). 
Control sections were incubated with a rat IgM isotypic control ( 1: 1 0; Accurate Chemical) 
instead of anti-CD77 /Gb3. 
Stx binding was detected in all tissues tested, and the results were similar for tissues 
from colostrum-deprived and colostrum-fed pigs. Although staining reactions with 
polyclonal anti-Stx2 were more intense than those with monoclonal anti-Stx2, both 
antibodies stained similar sites. Both Stxl and Stx2 bound to immature glomeruli in the 
outer cortex; to tubules, mature glomeruli, vessels, and arterioles in the inner cortex (Fig. 1 B 
and C); to capillaries and meninges in the cerebellum; to vascular cells surrounding ducts and 
sinusoidal cells (most likely Kupffer cells) within the parenchyma in the liver (Fig. ID); to 
cells in the lamina muscularis mucosae, muscle cells, and individual cells within the lamina 
propria of all intestinal sites examined; to Peyer' s patches and smooth muscle near the 
Peyer' s patches in the ileum (Fig. 1 G); and to lymphoid aggregates in the jejunum, spiral 
colon, and cecum. In addition, Stxl bound to some sites where Stx2 did not bind, namely, 
mucosal and serosal blood vessels in the ileum and spiral colon, and small blood vessels in 
the liver. Anti-CD77/Gb3 bound to all sites where Stx bound (e.g., compare Fig. IA to lB 
and C) and also to nerve fibrils in the cerebellar white matter (Fig. IE), which was a site 
where neither Stx toxin bound (Fig. IF). 
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FIG. 1. Immunohistochemical identification of Stx binding sites and Gb3 in neonatal 
porcine tissues. Anti-CD77 /Gb3 (A), Stx 1 (B) and Stx2 (C) binding to tubules 
(arrows) and glomeruli (arrowheads) in sections of kidney (g = glomerulus). (D) 
Stx2 binding to sinusoidal cells lining a vessel (thick arrow) and within the 
parenchyma (thin arrow) ofliver. (E) Stx2 binding within a Peyer' s patch (thin 
arrows), to smooth muscle (arrowhead), and to cells within the villous lamina 
propria (thick arrows). Digital images were captured directly with a Digital 
SPOT RT Slider camera (Diagnostic Instruments, Inc. , Sterling Heights, Ml) 
using Meta Vue™ version 5.0.7 imaging software (Universal Imaging Corp. , 
Downingtown, PA). (Bar= 50 µm) 
35 
36 
The Stx overlay and anti-CD77/Gb3 assays were modified for indirect 
immunofluorescence detection and used to determine if Stx can bind to isolated porcine 
tissue leukocytes and if these cells contain Gb3. For these studies, alveolar macrophages 
obtained from three 4- tol2-week-old pigs by lung lavage (22) (provided by A. Vorwald 
and S. Brockmeier, NADC) were seeded onto eight-chambered slides (Nalgene Nurre, 
Rochester, N.Y.) at a density of 4 x 104 cells/slide chamber, incubated (2 h, 37°C, 5% 
CO2) , rinsed with phosphate-buffered saline (PBS), fixed by brief ( ~ 1 sec) immersion in 
60% (vol/vol) acetone-PBS, and stored at -80°C. 
For Stx binding, alveolar macrophage slides were incubated with Stx2, rabbit anti-
Stx2 (as described above), and fluorescein isothiocyanate (FITC)-conjugated goat anti-
rabbit IgG (1 :80; Sigma, St. Louis, Mo.). For Gb3, the slides were incubated with anti-
CD77/Gb3 (as described above) and FITC-conjugated goat anti-rat IgM (1 :20; Southern 
Biotechnology, Birmingham, Ala.). Hanks' balanced salt solution without Ca2+ or Mg2+ 
(HBSS) and HBSS containing 1 % fetal bovine serum (HyClone, Logan, Utah) were used 
for wash steps and reagent dilutions, respectively. Negative controls were incubated with 
dilution buffer instead of Stx2 or with heterologous antibodies instead of anti-Stx2 or anti-
CD77 /Gb3. Slides were examined under an Eclipse E800 microscope (Nikon Instruments, 
Inc., Melville, N.Y.) with FITC filters (excitation, 465 to 495 nm; emission 515 to 555 nm). 
Cells with bound Stx2 or anti-CD77/Gb3 fluoresced green. Stx2 and anti-CD77/Gb3 bound 
to 2::80% of the alveolar macrophages on all evaluated slides. No green fluorescence was 
seen on negative control slides. 
Indirect immunofluorescence assays were also used to determine if Stx bound to 
peripheral blood leukocytes (PBL) and if PBL contained Gb3. Blood samples were 
collected in heparin from three adult pigs (2::6 months old) on 2 days. Granulocyte and 
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mononuclear leukocyte fractions were isolated (within 2 h of sample collection) by density 
gradient centrifugation with Ficoll-sodium diatrizoate (Amersham Pharmacia Biotech, 
Piscataway, N.J.) (13). Red blood cells were removed from granulocyte fractions by 
hypotonic lysis. Fractions were adjusted to 107 cells/ml in RPMI-1640 (Life Technologies, 
Gaithersburg, Md.) containing 4% autologous serum (mononuclear leukocytes) or 10% 
fetal bovine serum (granulocytes). Direct smears (10 to 15 µ1/slide; ~105 cells) were 
prepared on glass slides, fixed in 60% acetone-PBS, 1.5% formalin, or 100% methanol or 
by air drying, and stored (for up to 1 year) at the ambient temperature. In preliminary 
studies, Stx2 bound similarly to PBL fixed in 60% acetone-PBS, 1.5% formalin or by air 
drying, but it did not bind to cells fixed in 100% methanol. The cellular morphology was 
maintained better on air-dried smears, so these were used for all studies reported here. 
Differential staining showed that mononuclear leukocyte fractions contained ~95% 
mononuclear cells (:S4% monocytes) and that granulocyte fractions contained ~90% 
granulocytes (64 to 86% PMN and 8 to 35% eosinophils). 
Stx2 and anti-CD77/Gb3 binding was evaluated for duplicate PBL smears from 
each of six blood draws by use of the immunofluorescence assays described above for 
alveolar macrophages. Stxl binding was evaluated for PBL smears from a single blood 
draw by the use of crude Stxl (29) (provided by Nancy Cornick, Iowa State University, 
Ames, Iowa), anti-Stxl Mab13C4, and FITC-conjugated goat anti-mouse IgG (Vector, 
Burlingame, Calif.) ( diluted 1: 10 in HBSS containing 10% [ vol/vol] NSS). At least 600 
cells per granulocyte smear and 20 high power fields (HPFs; each containing 30 to 50 cells) 
per mononuclear leukocyte smear were examined for fluorescence. The results were 
calculated as the percentages of green fluorescent cells on granulocyte smears or the total 
numbers of fluorescent cells/20 HPFs on mononuclear leukocyte smears. The numbers of 
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cells and cellular morphologies in the fields examined for fluorescence were determined by 
differential interference contrast microscopy (Fig. 2). Eosinophils were differentiated from 
PMN by their red autofluorescence when the slides were examined with tetramethyl 
rhodamine isothiocyanate filters ( excitation, 528 to 563 nm; emission 600 to 660 nm) (1 ). 
As shown in Fig. 2, Stxl, Stx2 and anti-CD77/Gb3 bound to similar numbers of 
cells on PBL smears. On granulocyte smears, 58 to 91 % of the cells examined were 
positive. All positive granulocytes were PMN (i.e., none of the positive granulocytes 
fluoresced red when examined with tetramethyl rhodamine isothiocyanate filters), and for 
each sample the percentage of positive cells correlated with the percentage of PMN, as 
determined by differential counts. On mononulcear leukocyte smears, :Sl O cells/HPF were 
positive, and positve cells were morphologically identified as monocytes. The number of 
positive cells correlated with the number of monocytes by differential counts, providing 
further evidence that Stx and anti-CD77 /Gb3 bound to monocytes but not to lymphocytes. 
No green fluorescence was observed on negative control slides. 
In this study, we showed that Stxl and Stx2 bound to similar locations in multiple 
porcine tissues, although some differences were noted. We identified some novel porcine 
Stx binding sites, including kidney tubules, intestinal lymphoid aggregates, sinusoidal cells 
in the liver, and isolated leukocytes. The observation that Stx bound to porcine kidney 
tubules, as it does to bovine (15, 27) and human (19) kidney tubules, is consistent with the 
presence of kidney tubule damage in pigs experimentally infected with STEC (6, 14) and 
with the sensitivity of human kidney proximal tubule epithelial cells to Stx (16). Although 
intestinal lymphoid aggregates and liver cells are not recognized as targets for Stx-mediated 
damage, these tissues might be involved in Stx-induced immunomodulation or transport or 
in the clearance of Stx. We did not identify any unique Stx2 binding sites that correlated 
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FIG. 2. Indirect immunofluorescent detection of Stx binding and Gb3 on porcine 
peripheral blood leukocytes. Anti-CD77/Gb3 (A), Stxl (B), and Stx2 (C) 
binding to cells on granulocyte smears. Anti-CD77/Gb3 (E), Stxl (F), and Stx2 
(G) binding to cells on mononuclear leukocyte smears. DIC illumination, (D) 
and (H), of the same fields as (B) and (F), respectively. Images obtained as in 
Fig. 2. (Bar = 25 µm) 
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with the enhanced virulence associated with Stx2. In fact, Stxl bound to more vascular 
sites than did Stx2 (even when Stx2 was tested at 10-fold higher concentrations and 
detected with polyclonal anti-Stx2 antibodies). Nonetheless, it cannot be ruled out that 
discrepancies between Stxl and Stx2 binding were due to differences in the sensitivities of 
the immunohistochemical assays because of differences in the relative binding affinities of 
the reagents (which were not assessed in this study) or differences in the form of Stx 
receptors in the various tissues ( 4). 
This study provided direct evidence that Stx can bind to porcine leukocytes. Stx 
bound to PBL (monocytes and granulocytes), to tissue leukocytes (alveolar macrophages), 
and to tissue locations where leukocytes reside (i.e., the intestinal lamina propria, intestinal 
lymphoid aggregates, and the liver). These results are consistent with reports that Stx binds 
to human PMN and monocytes (28, 32, 34) and to bovine intestinal lymphoid aggregates 
(15) and with the demonstration that liver and splenic macrophages are involved in Stx2 
cytotoxicity in mice (25). We hypothesize that Stx binding to leukocytes is involved in 
STEC disease pathogenesis in pigs. 
Our results extend the evidence that Stx binds to Gb3 receptors in porcine tissues (3) 
and that not all Gb3 molecules are Stx receptors ( 4 ). The distribution of Stx binding sites 
correlated with the distribution of Gb3 in porcine tissues and leukocytes. The 
immunohistochemical detection of Gb3 at all sites where Stx bound confirmed earlier 
reports of Gb3 detection by high-performance liquid chromatography (HPLC) in the 
porcine liver, colon, and kidney (3) and by thin-layer chromatography in the kidney (14). 
The detection of Gb3 in the cerebellum, a site at which Gb3 was not detected by HPLC (3), 
suggests that the anti-CD77 /Gb3 immunoassay may be more sensitive than HPLC for 
detecting Gb3 and disputes the notion that acetone fixation removes Gb3 from porcine 
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tissues (15). To our knowledge, this is the first report of anti-CD77 /Gb3 binding to 
cerebellar nerve fibrils. Although we did not detect Stx binding to nerve fibrils , Stx may 
have bound at levels below the detection limit of our assay. 
Porcine peripheral blood leukocytes and the Stx binding assays described in this 
report will be useful for studying Stx binding mechanisms and for evaluating the effects of 
Stx binding on leukocyte functions. An advantage of using porcine leukocytes for these 
studies is that porcine STEC infection models are available for testing the relevance of the 
in vitro findings. 
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CHAPTER 3: DEVELOPMENT OF RAPID FLOW CYTOMETRIC 
ASSAYS TO MONITOR SHIGA TOXIN BINDING AND 
GLOBOTRIAOSYLCERAMIDE EXPRESSION ON PORCINE 
PERIPHERALBLOODPOLYMORPHONUCLEARLEUKOCYTES 
Introduction 
Shiga toxins (Stxs) are potent virulence factors that are expressed by Stx-producing 
Escherichia coli strains and cause systemic disease in humans [reviewed in (10, 33)] and 
pigs (3-5, 7, 21, 34). The pathogenesis of Stx-mediated disease is not fully understood, but 
polymorphonuclear leukocytes (PMN) may play a role. Human peripheral blood PMN bind 
Stx (29-31) and Stx binding induces functional effects on PMN, including modulation of 
phagocytosis and the respiratory burst (12) and delayed apoptosis (16). Isolated porcine 
peripheral blood PMN also bind Stx (3 8), but the effects of Stx binding on porcine PMN 
are unknown. 
The identification of Stx-induced effects on porcine PMN requires functional 
studies. To facilitate such studies, a means to monitor Stx binding and expression of the 
Stx receptor, globotriaosylceramide (Gb3; also known as CD77) on viable PMN is needed. 
Stx and anti-CD77 overlay immunofluorescence assays were used previously (38) to 
demonstrate that Stx binds to fixed porcine peripheral blood PMN and that these cells 
express Gb3. However, because the overlay assays were completed with fixed PMN and 
not with viable cells, other assays that are amenable for functional studies are needed. 
Flow cytometric assays can be used with viable cells and are amenable for 
functional studies with porcine PMN. Such assays allow simultaneous measurement of 
several parameters including cell size and granularity and one or more fluorescence stains. 
Stx binding to other isolated cell types including human peripheral blood monocytes (24), 
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PMN (30), platelets (2, 8, 11) and erythrocytes (1) and to bovine lymphocytes (19, 28), has 
been identified by flow cytometric assays. Stx binding to cells in these studies was detected 
either by incubation of samples in fluorescein isothiocyanate (FITC)-labeled Stx ( or Stx B 
subunit) (2, 8, 28, 30) or by sequential incubations in purified Stx (or Stx B subunits), anti-
Stx antibodies and FITC-labeled secondary antibodies (11, 18, 24, 28, 29). Flow 
cytometric assays have also been used for the study of the functional effects of Stx binding 
on isolated human PMN (30) and monocytes (24), bovine lymphocytes (19, 28) and ovine 
PMN (20), and to monitor Gb3 expression on bovine lymphocytes (19, 28). 
The first objective of this study was to develop flow cytometric assays to monitor 
Stx binding (by using Stx2 as a representative Stx) and Gb3 expression on isolated porcine 
peripheral blood PMN. Because purified Stx may not be readily available for some 
investigations and the use of crude Stx preparations was reported in other studies (15, 23, 
25, 38), the second objective was to assess the suitability of using crude Stx preparations 
for Stx binding studies. The flow cytometric protocol in this report was based on a 
modification of the methods described by Pesch, et. al. (22) and Stabel, et. al., (27) in which 
primary antibodies and fluorophore-labeled secondary antibodies were combined and co-
incubated with cells. The use ofreagent co-incubations reduces the amount of time 
required to complete an assay and minimizes the number of times that samples are 
manipulated. 
Materials and Methods 
Granulocyte isolation 
Granulocytes were isolated (within 2 h from collection) from heparinized peripheral 
blood collected from healthy pigs (?:3 month-old) as described elsewhere (9). A total of 10 
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pigs were used as donors throughout the course of this study. All reagents were brought to 
ambient temperature prior to use. In brief, granulocytes were fractionated by gradient 
centrifugation with Ficoll-sodium diatrizoate. The plasma and buffy coat layers were 
discarded and the granulocyte-rich red cell pellet was retained. Red blood cells were 
removed by hypotonic lysis by mixing cells with 36 ml sterile dH2O for 20 s followed by 
addition of 4 ml 1 OX Hank's balanced salts solution (HBSS; without ca2+, Mg2+ or phenol) 
to restore isotonicity, and centrifuged (1200 x g for 20 min). The supernatant was 
discarded, the cells were resuspended in 5 ml IX HBSS, and the lysis procedure was 
repeated. The granulocytes were washed once in IX HBSS, centrifuged (400 x g for 10 
min) and the supernatant discarded. Washed granulocytes were resuspended in flow assay 
buffer (0.0lM phosphate-buffered saline containing 1 % fetal calf serum [Hy-Clone] , 1 % 
normal goat serum [Vector] and 0.1 % sodium azide ). Cell concentrations were estimated 
by using a Coulter counter (BeckmanCoulter) or a hemacytometer and adjusted to 4 x 106 
cells/ml in flow assay buffer. The cell concentrations of suspensions were double-checked 
after adjustment to minimize dilution errors, and only suspensions containing 3.9--4.1 x 106 
cells/ml were used for further analysis. Differential staining showed that preparations 
contained 2:90% granulocytes and :Sl 0% mononuclear leukocytes. The granulocytes 
consisted mostly of PMN (80-96%) with some eosinophils (4-20%) and rare basophils 
( <1 % ). The viability estimates of the granulocyte suspensions were consistently 2:90% as 
assessed by 7-AAD staining (26) or by Trypan blue exclusion. 
Development of the Stx2 binding flow cytometric assay 
Basic assay protocol. Flow assay buffer ( described above) was used for all reagent 
dilutions. A separate step to block Fe receptors on PMN was omitted due to the presence of 
49 
serum in the flow assay buffer. The basic protocol used to define the assay parameters was 
as follows. Granulocyte suspensions (50 µl) were dispensed into wells of round-bottomed 
96-well microtiter plates (Coming Costar) for a final cell concentration of 2 x 105 
cells/well. This cell concentration was used in all experiments with the exception of the 
experiment in which several cell concentrations were assessed. Fifty-I 00 µl of flow assay 
buffer containing Stx2 (kindly provided by A. O'Brien, Uniformed Services University of 
the Health Sciences, Bethesda, MD) was added to the cells and the cells were incubated on 
ice (static) in preliminary experiments or at 4°C with constant agitation for 15 min-lh. One 
hour incubations with Stx2 and final well volumes of 150 µl were used for most assays. 
Constant agitation was achieved by using a microplate shaker with a 3 mm orbital diameter 
(setting 300 rpm; model MTS 4; IKA Works, Inc.). Unbound Stx2 was removed by 
centrifuging the cells ( 400 x g for 3 min) and decanting the supernatant by flicking the plate 
over absorbent toweling. Cells were washed twice in ice-cold flow assay buffer (200 
µ1/well per wash) followed by centrifugation and removal of the supematants. Cells were 
resuspended in 100-150 µl ice-cold flow assay buffer containing both rabbit anti-Stx2 
antiserum (provided by A. O'Brien) and goat anti-rabbit lgG-FITC or R-phycoerythrin 
(PE)-labeled secondary antibodies (Southern Biotechnology Associates [SBA]) and 
incubated on ice for 30 min. Cells were centrifuged, decanted and resuspended in 
FACsLyse (Becton-Dickinson) to fix the cells. Fixed cells were transferred to 12 x 75 mm 
polystyrene tubes (Falcon), protected from light and stored at 4 °C for up to four days until 
flow cytometric analysis. Most cells were analyzed within 48 hr after fixation. 
Antibody titrations. Antibodies for the Stx2 binding flow cytometric assay were 
titrated by checkerboard titrations in two independent assays. Rabbit anti-Stx2 was tested 
at 1 :500 to 1 :4000 dilutions, goat anti-rabbit lgG-FITC at 0.1-2 µg/ml (final well 
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concentration), and goat anti-rabbit IgG-PE at 63 ng/ml-2 µg/ml. Titrated antibodies were 
initially tested against 1200 ng/ml Stx2 (120 ng per well) and again at 3000 ng/ml (300 ng 
per well) in final well volumes of 100 µl. The saturating antibody concentrations that were 
identified in 100 µl well volumes were confirmed by assays with 150 µl well volumes. In 
brief, 100 µl flow assay buffer containing Stx2 was added to microtiter plate wells followed 
by 50 µl flow assay buffer containing 2 x 105 cells. After incubation in Stx2 at 4 °C and 
wash steps to remove unbound Stx2, 50 µl of flow assay buffer containing anti-rabbit-PE or 
anti-rabbit IgG-FITC and 100 µl of flow assay buffer containing rabbit anti-Stx2 were 
added to the cells. Cells were incubated for 30 min as described above. 
Saturating antibody concentrations were estimated by calculating the signal to noise 
ratios associated with each anti-Stx2 and secondary antibody combination. The 
fluorescence intensity values associated with cells incubated in Stx2 constituted the signal 
values, and the fluorescence intensity values associated with cells incubated in flow assay 
buffer instead of Stx2 constituted the noise values. The antibody concentrations associated 
with the highest signal to noise ratio were deemed saturating. 
Effect of cell concentration on Stx2 binding. Analysis of cell concentrations greater 
than 2 x 105 cells/well may dilute the reagents used in the Stx2 binding assay to below 
saturating concentrations. To assess the dependence of Stx2 binding on the starting cell 
concentration, granulocytes isolated from one pig were dispensed into microtiter plate wells 
at 0.5, 1, 2.5, 5 and 10-fold cell concentrations relative to 2 x 105 cells/well. Cells were 
incubated in 750 ng/ml Stx2 (75 ng per well in 100 µl final well volumes) and Stx2 binding 
was detected as described earlier. The results were reported as the percentage of Stx2-
positive PMN and relative fluorescence intensities. The fluorescence intensities for each 
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treatment were normalized to the fluorescence intensities obtained from cells incubated at a 
I-fold cell concentration. 
Effect of well volume on Stx2 binding. Some flow cytometric assays (e.g. , multi-
color flow assays) may require addition of> 100 µl of reagent solutions to cells in microtiter 
plate wells, increasing the final well volume to > 150 µ1. To evaluate the effects of final 
well volume on Stx2 binding, granulocytes isolated from one pig were dispensed into the 
wells of duplicate microtiter plates (2 x 105 cells/well) containing 0, 37.5, 75, or 150 ng 
Stx2 per well. The final well volumes were adjusted with flow assay buffer to 100, 150 or 
200 µl , and Stx2 binding was detected as described above. 
Titration of Stx2 in the Stx2 binding flow cytometric assay. Titrations of Stx2 were 
evaluated in two independent assays with PE- and FITC-conjugated secondary antibodies. 
Stx2 was tested at 2-fold dilutions ranging from 6-1500 ng/ml (0.9-225 ng per well in a 
final volume of 150 µl) with triplicate wells prepared for each Stx2 concentration tested. 
Fluorescence intensities from each treatment were normalized to the fluorescence 
intensities obtained from cell samples incubated in 750 ng/ml Stx2. The results were 
reported as the percentage of Stx2-positive PMN and as the relative fluorescence 
intensities. 
The 50% saturating concentration of Stx2 was estimated by using the normalized 
fluorescence intensity values. The fluorescence intensity value associated with the apparent 
plateau for each curve was multiplied by 0.5 to obtain an estimated 50% fluorescence 
intensity value. Curves of Stx2 concentrations versus normalized fluorescence intensities 
were plotted. As shown in Fig. 2A and B, a horizontal line was drawn connecting the 
estimated 50% fluorescence intensity value on the y-axis to the curve. A perpendicular line 
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was then drawn downward to the x-axis to obtain an estimate of the 50% saturating 
concentration of Stx2. 
Determination of the specificity of the Stx2 binding flow cytometric assay. The 
specificity of the flow cytometric Stx2 binding assay was assessed in three ways. First, to 
determine if rabbit lgG bound to PMN, cells were incubated in 750 ng/ml Stx2 (112.5 ng 
per well in a final well volume of 150 µl) followed by incubation in one of two rabbit 
hyper-immune sera that were directed against antigens unrelated to Stx2 or in normal rabbit 
serum instead of anti-Stx2. Second, following incubation in Stx2, cells were incubated in 
flow assay buffer containing mouse monoclonal anti-Stx2 A subunit (Mabl lElO) or anti-
Stxl B subunit (Mab 13C4) hybridoma supernatants (both kindly provided by James 
Samuel, Texas A&M University, College Station, TX) and goat anti-mouse IgG1-PE (SBA) 
and compared to cells incubated in rabbit anti-Stx2 and goat anti-rabbit IgG-PE. These 
Mabs were previously used to show specificity of Stx overlay assays for Stx2 and Stxl 
(38). A purified IgG1 preparation of Mab 1 lEl0 (kindly provided by A. O'Brien) was also 
used in some experiments. 
Third, a mouse monoclonal anti-Stx2 B subunit antibody (Mab BC5 BB12 ascites; 
kindly provided by N. Strockbine, Centers for Disease Control and Prevention, Atlanta, 
GA) (6) that has been used in other studies as a neutralizing antibody (15, 32, 37), was used 
to block Stx2 binding to porcine PMN. The method used in the present study was based on 
the method used to block Stx2 binding to bovine lymphocytes (C. Menge, personal 
communication). Two independent assays were completed. In brief, granulocytes were 
isolated from blood collected from two pigs (one pig per day on two days). Fifty 
microliters of a solution containing 750 ng/ml Stx2 and 50 µl of Mab BC5 BB12 (diluted 
125-4000-fold) were added to selected wells of a 96-well microtiter plate and incubated for 
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30-60 min at ambient temperature. Positive controls were prepared by adding 50 µl of the 
750 ng/ml Stx2 solution to wells containing 50 µl of Mab 13C4 ascites (diluted 125-fold) or 
50 µl of flow assay buffer instead of Mab BC5 BB12. Negative controls received flow 
assay buffer instead of Stx2. After the pre-incubation step, 50 µl of a granulocyte 
suspension was added to each well for a final cell concentration of 2 x 105 cells/well. Cells 
were incubated for 1 h at 4 °C with constant agitation, washed, and incubated with rabbit 
anti-Stx2 and anti-rabbit IgG-PE antibodies as described earlier. To identify binding of any 
Mab BC5 BB12:Stx2 complexes to PMN, some cells were incubated in goat anti-mouse 
IgG1-FITC in addition to rabbit anti-Stx2 and anti-rabbit IgG-PE. 
Effect of incubation time on Stx2 binding. The effect of incubation time on Stx2 
binding at 4°C was assessed in two independent assays. Cells were incubated in 750 ng/ml 
purified Stx2 (112.5 ng per well in a final volume of 150 µl per well) for 15, 30 or 60 min 
and Stx2 binding was detected as described above. All cell sample incubations with Stx2 
began at the same time, but subsequent washes and reagent incubations were staggered. 
The results were reported as the percentage of Stx2-positive PMN. 
Gb3 and multi-color flow cytometric assays 
Antibody titrations for Gb3 assays. For the development of a flow cytometric Gb3 
assay, anti-CD77 (Serotec) was tested at 5-50% (vol/vol) and goat anti-rat IgM-FITC at 1-
8 µg/ml (all final concentrations per well) in repeat checkerboard titrations. One-hundred 
fifty micro liter final well volumes were used. In brief, 100 µl of flow assay buffer 
containing anti-CD77 and 50 µl of cell suspensions (2 x 105 cells/well) were added to 
microtiter plate wells. Cells were incubated for 1 h, 4 °C with constant agitation, washed 
twice, resuspended in 150 µl flow assay buffer containing goat anti-rat IgM-FITC (SBA) 
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and incubated for 30 min on ice. Cells were centrifuged, decanted, and resuspended in 
F ACsLyse as describe above. 
Antibody titrations for multi-color flow cytometric assays. The ability to measure 
additional parameters, such as the expression of cell surface markers, along with Stx2 
binding or Gb3 expression on porcine peripheral blood PMN will be important for 
conducting functional studies. The porcine granulocyte-specific mouse monoclonal 
antibody PG68A (IgG1; Veterinary Medical Research and Development, Inc. [VMRD]) was 
used to assess the feasibility of double immunolabeling in the flow cytometric assays. The 
saturating concentrations of antibodies for the detection of PG68A were identified by repeat 
checkerboard titrations. PG68A was tested at 2-12 µg/ml, goat anti-mouse IgG1-FITC at 
2-16 µg/ml and goat anti-mouse IgG1-PE at 0.25-8 µg/ml (all final concentrations per 
well). One-hundred microliters of flow assay buffer containing PG68A and 50 µl of cell 
suspensions (2 x 105 cells/well) were added to microtiter plate wells. Cells were incubated 
for lh, 4°C with constant agitation, washed twice, resuspended in 150 µl flow assay buffer 
containing goat anti-mouse IgG1 FITC or PE-conjugated secondary antibodies (SBA) and 
incubated for 30 min on ice. Cells were centrifuged, decanted, and resuspended in 
F ACsLyse as describe above. 
Assessment of the feasibility of multi-color flow cytometric assays. Two 
independent assays were run to determine if co-incubation of PG68A and Stx2 or PG68A 
and anti-CD77 with cells affected the binding of PG68A, Stx2 or anti-CD77. Cells were 
incubated in either PG68A, 750 ng/ml Stx2 (112.5 ng per well) or anti-CD77 alone or in 
both PG68A and Stx2 or both PG68A and anti-CD77. Triplicate microtiter plate wells 
were prepared for each treatment. Controls included cells incubated in flow assay buffer 
instead of PG68A, Stx2 or anti-CD77, cells incubated in flow assay buffer containing an 
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IgG1 isotype control (VMRD) instead of PG68A and cells incubated in flow assay buffer 
containing an IgM isotype control (Cedar Lane Labs) instead of anti-CD77. After two 
washes to remove unbound ligands, cells were incubated in flow assay buffer containing 
rabbit anti-Stx2, goat anti-rabbit lgG-PE and goat anti-mouse IgG1-FITC (for Stx2 multi-
color flow assays) or in flow assay buffer containing goat anti-rat lgM-FITC and goat anti-
mouse IgG1-PE (for Gb3 multi-color flow assays) for 30 min on ice. Cells were fixed in 
F ACsLyse as described earlier. 
Reproducibility ofStx2 binding and Gb3 detection in the multi-color flow cytometric 
assays. The reproducibility of Stx2 binding and Gb3 detection was assessed by using 
granulocyte fractions isolated from five pigs over the course of four days. Granulocytes 
were isolated from peripheral blood collected from two of the pigs on days 1 and 2 and 
from the remaining three pigs on days 3 and 4 for a total of 10 granulocyte fractions. Cells 
from each granulocyte fraction were incubated in flow assay buffer containing Stx2 (750 
ng/ml; 112.5 ng per well in 150 µl final well volumes) or anti-CD77 and PG68A. 
Triplicate wells were prepared for each treatment, except for antibody controls, which were 
prepared in single wells. Controls included cells incubated in flow assay buffer instead of 
in Stx2 or anti-CD77, in flow assay buffer containing a rabbit hyper-immune serum instead 
of anti-Stx2, in an lgG1 isotype control instead of PG68A, or in IgM isotype control instead 
of anti-CD77. Results were reported as the percentage of PMN positive for each ligand. 
Flow cytometric analysis 
A minimum of 10,000 events were acquired on a F ACScan flow cytometer 
equipped with CellQuest™ Pro software (Becton-Dickinson). PMN were electronically 
defined by their characteristic forward and side light scatter properties (17). Negative 
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controls were used to set electronic gates such that :S:2% of the cells in the controls were 
positive. 
Post-assay sample PMN counts and viability 
Eleven and ten granulocyte fractions isolated over the course of four days from five 
pigs were evaluated for differential counts and viability staining, respectively. Immediately 
following the 30 min antibody incubation step in the flow cytometric Stx2 binding and Gb3 
assays, but prior to cell fixation, aliquots of cell suspensions were removed from each 
microtiter plate well for 7-AAD viability staining and for preparation of one Wright's 
stained smear per well. A minimum of 200 cells were evaluated for 7-AAD staining by 
flow cytometry (26), and a minimum of 100 cells for differential counts. Pre-assay PMN 
counts were set at 100 and post-assay PMN counts were normalized to the pre-assay counts 
associated with each respective granulocyte fraction. Viability estimates were reported as 
the percentage of viable cells in each sample. The results were evaluated to determine if 
any changes in the proportions of granulocytes that were PMN and in sample viability 
estimates could be noted. 
Assessment of the use of crude Stx2 for Stx2 binding studies 
Preparation of crude Stx2. An Stx2-positive crude preparation, crude Stx2(kw), 
was prepared from a streptomycin-resistant variant of the E. coli O157:H7 strain 86-24 (5), 
as described elsewhere (23). A Stx-negative preparation, crude Stx-negative, was prepared 
in parallel from a streptomycin-resistant variant of the E. coli O157:H7 strain 87-23 (5) for 
use as a negative control. In brief, bacteria were grown in trypticase soy broth (5 ml; 
Becton-Dickinson) without antibiotics for 6 hr, 37°C with shaking (200 rpm) and sub-
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cultured (500-ml) for 18 hr under the same conditions. Bacteria were harvested by 
centrifugation (10,000 x g for 30 min, 4°C). The cell pellets were retained, resuspended in 
0.023M phosphate-buffered saline, pH 7.4 (ratio of 1 ml pellet tol0 ml buffer), held on ice 
and lysed by sonication. Sonicates were clarified by centrifugation at 15,000 x g for 1 h, 
4°C. The supematants were retained and dialyzed extensively against PBS in 10,000 
MWCO dialysis cassettes (Pierce). Sodium azide was added to a final concentration of 
0.05%, and the crude extracts were filter-sterilized (0.22 µm). A similarly prepared crude 
Stx2 preparation, crude Stx2(mhi), was available and used as a positive control in some 
experiments. 
Immunofluorescence Stx overlay assays with granulocyte smears (38) were used to 
monitor the crude extracts throughout the preparation procedure. Crude extracts were 
tested at two- and ten-fold dilutions and the results were compared to smears incubated in 
purified Stx2 (3 µg/ml). Bright fluorescence was observed on smears incubated in a two-
fold dilution of crude Stx2(kw) and weak fluorescence was observed on PMN smears 
incubated in a ten-fold dilution of crude Stx2(kw). In comparison, bright fluorescence was 
observed on PMN on smears incubated in both two- and ten-fold dilutions of crude 
Stx2(mhi) or in purified Stx2. These results indicated that crude Stx2(kw) contained a 
lower concentration of Stx2 than did crude Stx2(mhi). No Stx2-positive PMN were 
identified in overlay assays with crude Stx-negative extract. 
Crude Stx2(kw) was concentrated by centrifugation in 30,000 MWCO concentrators 
(Macrosep; Filtron Technologies) to approximately one-third the original volume, filter 
sterilized and stored at -80°C. Crude Stx-negative was concentrated in parallel for use as a 
concentrated negative control. Crude Stx2(mhi) was not similarly processed. The resulting 
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concentrated preparations and crude Stx2(mhi) were used for all subsequent 
characterizations of crude Stx2 in this study. 
Characterization of protein and Stx2 concentrations in crude preparations. Protein 
concentrations of the crude preparations were estimated by using Bradford assay reagents 
(Bio-Rad) and bovine serum albumin as a reference standard. The Stx2 concentrations in 
crude Stx2(kw) and crude Stx2(mhi) were estimated by using a commercially available 
ELISA kit (Premier EHEC ELISA; Meridian Diagnostics, Inc.) (13) and purified Stx2 as a 
reference standard (14). The limit of detection of the ELISA kit was 75 pg/ml Stx2. 
Assessment of crude Stx2 binding to porcine P MN. Crude Stx2(kw) binding to 
PMN was assessed by using the Stx2 binding flow cytometric assay in 150 µl final well 
volumes. In preliminary assays, crude Stx2(kw) was tested at estimated Stx2 
concentrations of 77-1530 ng/ml, which corresponded to 5-100 µl crude Stx2(kw)/well. In 
two later independent assays (total of three granulocyte preparations), crude Stx2(kw) was 
evaluated at estimated Stx2 concentrations of 6-1500 ng/ml (0.9-225 ng Stx2 per well) to 
correspond to the earlier titrations of purified Stx2. As a control, some cells were incubated 
in crude Stx-negative (391 µg crude protein/well). This protein quantity corresponded to 
the amount of bacterial protein in cells incubated in an estimated 750 ng/ml crude 
Stx2(kw). Stx2-positive PMN were identified by PE staining. Duplicate or triplicate 
microtiter plate wells were prepared for each treatment. Fluorescence intensities from each 
treatment were normalized to the fluorescence intensities obtained from cell samples 
incubated in an estimated 750 ng/ml crude Stx2(kw). The results were reported as the 
percentage of crude Stx2-positive PMN and as the relative fluorescence intensities. 
Reproducibility of crude Stx2 binding in the multi-color flow cytometric assay. The 
reproducibility of crude Stx2 binding to PMN was assessed in four independent assays 
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(total of 10 granulocyte isolations from five pigs). Cells were incubated in crude Stx2(kw) 
containing an estimated 750 ng/ml Stx2 (112.5 ng per well in 150 µl final well volumes) 
and PG68A. Crude Stx2(mhi) was also tested in parallel on two different days (total of two 
granulocyte preparations) at the same Stx2 concentration. Positive control samples were 
incubated with 750 ng/ml purified Stx2 instead of crude Stx2. Negative controls were 
incubated in flow assay buffer containing 391 µg crude Stx-negative instead of either of the 
crude Stx2 preparations. Triplicate microtiter plate wells were prepared for each treatment. 
The results were reported as the percentage of Stx2-positive PMN. 
Effects of incubation time and temperature on crude Stx2 binding. Preliminary 
findings with crude Stx2(kw) showed that 2:93% of PMN were Stx2-positive following 
incubation in an estimated 77-1530 ng/ml crude Stx2(kw). These concentrations 
corresponded to 5-100 µl of crude Stx2(kw). A linear fluorescence intensity response was 
observed in cell samples incubated in an estimated 77-306 ng/ml crude Stx2 ( equivalent to 
5-20 µl). Based on the fluorescence intensities values in the linear range, the half-maximal 
concentration of crude Stx2(kw) was calculated as an estimated 192 ng/ml Stx2 (an 
equivalent of 12.5 µl). This concentration was rounded up to an estimated 230 ng/ml Stx2 
( an equivalent of 15 µl) and used to assess the effects of incubation time and temperature on 
the binding of crude Stx2(kw). 
Cells were incubated in crude Stx2(kw) containing an estimated 230 ng/ml Stx2 
(34.5 ng per well) at 4°C or 37°C for 15, 30 or 60 min. All incubations of cells in crude 
Stx2(kw) began at the same time, but subsequent washes and antibody incubations were 
staggered. The wash steps were completed with ice-cold flow assay buffer and the 
antibody incubations were completed on ice as described earlier. Results were reported as 
the percentage of Stx2-positive PMN and as relative fluorescence intensities. Fluorescence 
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intensities of cells incubated in crude Stx2(kw) for 15 and 30 min were normalized to the 
fluorescence intensities obtained from cells incubated in crude Stx2(kw) for 60 min. 
Results 
Stx2 binding and Gb3 flow cytometric assays 
Antibody concentrations. For the detection of Stx2 binding, the estimated saturating 
dilution of rabbit anti-Stx2 was 1: 1000 (final dilution per well) and the estimated saturating 
concentrations of goat anti-rabbit IgG-FITC and goat anti-rabbit IgG-PE were 2 µg/ml and 
1 µg/ml, respectively (final concentrations per well). Estimated saturating antibody 
concentrations for the detection of Gb3 were anti-CD77 at 20% (vol/vol) and anti-rat IgM-
FITC at 8 µg/ml (final concentrations per well). For double-immunolabeling studies, the 
estimated saturating antibody concentrations were 8 µg/ml for both PG68A and anti-mouse 
IgG1-FITC and 2 µg/ml for anti-mouse IgG 1-PE (final concentrations per well). 
Effects of cell concentration and final well volume on Stx2 binding. The percentage 
of Stx2-positive PMN was 2:97% (average of duplicate wells for each treatment) in cell 
samples containing 0.5-5-fold cell concentrations relative to 2 x 105 cells and decreased to 
82% in cell samples containing a 10-fold concentration of cells (Fig. 1 ). The relative 
fluorescence intensity of samples decreased as cell concentration increased. These results 
indicated that the use of 1 x 105 cells/well to 1 x 106 cells/well is suitable for incubations in 
Stx2 at the concentration tested (750 ng/ml Stx2). No apparent effects of well volume on 
Stx2 binding were observed. The percentages of Stx2-positive PMN were 2:98% following 
incubation in 3 7 .5-150 ng Stx2 per well at each final well volume tested (100-200 µl). All 
subsequent assays were completed with 2 x 105 cells in final well volumes of 150 µI. 
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FIG. 1. The effect of cell concentration on Stx2 binding. Granulocyte suspensions were 
dispensed into a microtiter plate at 0.5-10-fold cell concentrations relative to 
2 x 105 cells/well and incubated in 750 ng/ml Stx2. Stx2 binding was identified 
by PE staining and detected by flow cytometry. The fluorescence intensity 
associated with each treatment was normalized to the fluorescence intensity 
obtained from cells incubated at a I-fold cell concentration. The results shown 
are expressed as the percentage of PMN that are Stx2-positive and as relative 
fluorescence intensity. 
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Titration of Stx2 in the Stx2 binding assay. As shown in Fig. 2A and B, the 
percentage of Stx2-positive PMN reached a maximum (2:95%) following incubation of cells 
in 187.5 ng/ml Stx2 (28.1 ng per well), and the fluorescence intensity values reached a 
plateau in cells incubated in 750 ng/ml Stx2 (112.5 ng per well) . Some Stx2-positive PMN 
(9-14%) were identified following incubation in as little as 23 .4 ng/ml Stx2 (3 .5 ng per 
well) with FITC detection or 11.7 ng/ml Stx2 (1.8 ng per well; 29-92%) with PE detection, 
but these percentages were highly variable between granulocyte isolations. The 50% 
saturating concentrations, estimated on the basis of relative fluorescence intensities, were 
105 and 115 ng/ml Stx2 in the two assays with PE detection and 125 and 145 ng/ml in the 
two assays with FITC detection. 
Specificity of the Stx2 binding assay. The Stx2 binding flow cytometric assay was 
specific for Stx2 binding to porcine PMN. No Stx2-positive PMN were identified in cells 
incubated in Stx2 and in either of the two rabbit hyper-immune sera (n 2: 3 independent 
assays) or normal rabbit serum (n = 2 independent assays). Hyper-immune sera controls 
were routinely included in subsequent assays. Cells incubated in Stx2 and Mab 11E10 or 
rabbit anti-Stx2 contained 93% and 98% Stx2-positive PMN, respectively, but there were 
no Stx2-positive PMN identified in cell samples incubated in the Stxl-specific antibody, 
Mab 13C4. Incubation of cell samples in a purified IgG1 preparation of Mab 11E10 
resulted in the identification of some Stx2-positive PMN ( ~50% ). A high background 
signal was observed with purified Mab 11E10 and may have precluded the identification of 
higher percentages of Stx2-positive PMN. In the blocking experiment, no Stx2-positive 
(PE-positive) or Mab BC5 BB12:Stx2 complex-positive (FITC-positive) PMN were 
identified following pre-incubation of Stx2 with Mab BC5 BB 12. Stx2-positive PMN were 
identified following pre-incubation of Stx2 in Mab 13C4 or in flow assay buffer. These 
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FIG. 2. Titration of Stx2 in the Stx2 binding flow cytometric assay. Stx2 binding to 
porcine PMN was detected by the use of PE-conjugated (A) or FITC-conjugated 
(B) secondary antibodies and flow cytometry. The fluorescence intensities of 
cells from each well were normalized to the mean fluorescence intensity value 
obtained from cells incubated in 750 ng/ml Stx2. The results shown are 
expressed as the percentage of Stx2-positive PMN from two independent assays 
and as the relative fluorescence intensities from one representative of two 
independent assays for each PE and FITC detection. Plotted points represent the 
mean of triplicate wells for each Stx2 concentration tested. Error bars reflect + 1 
standard deviation (% Stx2+) or -1 standard deviation (relative fluorescence) of 
each mean. Insets: examples of the use of relative fluorescence intensity values 
to estimate the 50% saturating concentration of Stx2. 
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results indicated that Mab BC5 BB 12 blocked Stx2 binding to porcine PMN and that no 
Mab BC5 BB12:Stx2 complexes bound to PMN. No Stx2-positive PMN were identified in 
negative control samples. 
Feasibility of multi-color flow cytometric analysis. Co-incubation of cells in both 
Stx2 and PG68A or both anti-CD77 and PG68A did not affect the percentages of PMN 
positive for each ligand. At least 99% of PMN in cell samples incubated in Stx2 alone or in 
both Stx2 and PG68A were Stx2-positive, and 2'.:99% of PMN in cell samples incubated in 
PG68A alone or in both Stx2 and PG68A were PG68A-positive. Similarly, >99% of the 
PMN were Gb3-positive in cell samples incubated in anti-CD77 alone or in both anti-CD77 
and PG68A, and ~98% of PMN were PG68A-positive in cell samples incubated in PG68A 
alone or in both PG68A and anti-CD77. 
Reproducibility of Stx2 binding and Gb3 detection in the multi-color flow cytometric 
assays. The flow cytometric assays were reproducible. No differences between pigs or 
between blood draws from each pig were observed. Representative dot plots are shown in 
Fig. 3. Greater than 98% of PMN were Stx2-positive in all cell samples incubated in both 
Stx2 and anti-Stx2. Similarly, all cell samples incubated in anti-CD77 consistently 
contained ~99% Gb3-positive PMN. Double-immunolabeling with PG68A and Stx2 
showed that >98% of PMN were PG68A and Stx2 double-positive. Double-
immunolabeling with PG68A and anti-CD77 showed that 96 to ~99% (median 2'.:99%) of 
PMN were PG68A and Gb3 double-positive. Multiple Stx2-positive populations were 
observed in some cell samples (see Fig. 3G). Controls contained :S2% PMN in the Stx2-
positive or Gb3-positive gates and :S3% PMN in the PG68A-positive gate. 
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FIG. 3. Two dimensional dot plots demonstrating multi-color flow cytometric detection 
of Stx2 binding or Gb3 and PG68A on porcine PMN. Greater than 98% of the 
gated cells were positive after incubation in 750 ng/ml purified Stx2 (A), 
estimated 750 ng/ml crude Stx2 (C) or anti-CD77 (E) and the granulocyte 
marker PG68A. Data are representative of one of three replicate wells analyzed 
from one of ten granulocyte preparations. Controls show that :S2% of the cells 
were positive after incubation in assay buffer instead of Stx2 and PG68A (B), 
crude Stx-negative instead of crude Stx2 (D), or an lgM isotype control antibody 
and assay buffer instead of anti-CD77 and PG68A (F). (G) Example of the 
multiple Stx2-positive cell populations observed in some samples. 
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Effect of incubation time on Stx2 binding. All cell samples contained 299% Stx2-
positive PMN (both assays) following incubation in Stx2 for 15-60 min. No changes in the 
fluorescence intensities of cell samples over time were noted (Fig. 4A). 
Post-assay sample viability and P MN counts No apparent effects of treatment on 
cell sample viability or PMN counts were noted. Pre-assay viability estimates ranged from 
92% to 299% (median 99%). Post-assay viability estimates ranged from 80% to 299% 
(median 97%) over all cell samples evaluated (n = 113). The median viability estimate for 
cell samples incubated in 750 ng/ml Stx2 (112.5 ng per well) was 98%, of which 34/37 had 
post-assay viability estimates of290%. The median viability estimate of cell samples 
incubated in anti-CD77 (n = 39) was 97% and 36/37 of the antibody control samples had 
viability estimates of~90% (median 97%). PMN differential counts of smears prepared 
from samples incubated in Stx2 or anti-CD77 were normalized to pre-assay PMN counts. 
Smears from antibody control samples were not evaluated for PMN counts. The median 
normalized post-assay PMN counts was 100 and ranged from 84-120 for all treatments 
evaluated (n = 57). 
Assessment of the use of crude Stx2 
Characterization of crude Stx2 and crude Stx-negative. The protein concentrations 
of crude Stx2(kw), crude Stx-negative and crude Stx2(mhi) were estimated at 8.0, 4.0, and 
2.0 mg/ml, respectively. EHEC ELISA analysis showed that crude Stx2(kw) and crude 
Stx2(mhi) contained an estimated 2.3 µg/ml Stx2 (0.03 ng Stx2/mg protein) and 7.0 µg/ml 
Stx2 (3.5 ng Stx2/mg protein), respectively. 
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FIG. 4. Overlay histograms from one of two independent analyses demonstrating the 
effects of incubation time on Stx2 (A) or crude Stx2(kw) (B) binding at 4°C and 
on crude Stx2(kw) binding at 37°C (C). Cell samples were incubated in Stx2 or 
crude Stx2(kw) for 15, 30 or 60 min and binding was detected with PE. The 
Stx2-positive gate is depicted by a horizontal bar on each histogram. 
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Crude Stx2 binding to porcine PMN. As shown in Fig. 5, initial analyses of crude 
Stx2(kw) showed that Stx2-positive PMN (2:93%) were identified in all cell samples 
incubated in an estimated 77-1530 ng/ml crude Stx2(kw). The fluorescence intensities 
increased with increasing crude Stx2 concentration indicating that crude Stx2(kw) was 
titratable. Consistent with the finding that purified Stx2 binding could be detected by using 
FITC- or PE-conjugated secondary antibodies, crude Stx2 binding was detected by using 
FITC- or PE-conjugated secondary antibodies (Fig. 6). Subsequent titrations of crude 
Stx2(kw) showed that the response curve observed with crude Stx2(kw) was similar to the 
response curve observed with purified Stx2 (Fig. 7 A). Peak fluorescence intensities were 
observed with cells incubated in crude Stx2(kw) containing an estimated 375 ng/ml Stx2 
(Fig. 7B). The estimated 50% saturating concentrations of crude Stx2(kw) were 115 ng/ml 
with the single granulocyte fraction in assay 1 and 45 and 190 ng/ml with the two isolated 
granulocyte fractions in assay 2. No Stx2-positive PMN were identified in cell samples 
incubated in crude Stx-negative. 
Reproducibility of crude Stx2 binding in the Stx2 binding flow cytometric assay. 
Reproducible results were obtained with all cell samples incubated in an estimated 750 
ng/ml crude Stx2(kw) in the Stx2 binding flow cytometric assay. No differences between 
pigs or between blood draws from each pig were observed. A representative dot plot is 
shown in Fig. 3C. All cell samples incubated in crude Stx2(kw), crude Stx2(mhi) or 
purified Stx2 contained 2:98% Stx2-positive PMN. Similar to the observation that multiple 
Stx2-positive populations were observed in some cell samples incubated in purified Stx2, 
multiple crude Stx2-positive populations were observed in some cell samples incubated in 
crude Stx2(kw). Cell samples incubated in crude Stx-negative contained :::;2% Stx2-positive 
PMN (Fig. 3D). 
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FIG. 5. Crude Stx2 binding to porcine PMN. Granulocyte preparations were incubated 
in an estimated 153-767 ng/ml crude Stx2(kw) for assay 1 and 77-1530 ng/ml 
crude Stx2(kw) for assay 2. Stx2-positive PMN were identified by flow 
cytometric detection of PE-stained cells. 
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FIG. 6. Detection of crude Stx2 binding to PMN by the use of either FITC- (A) or PE-
(B) conjugated secondary antibodies in the Stx2 binding flow cytometric assay. 
Granulocytes were incubated in an estimated 750 ng/ml crude Stx2 (solid line) 
or in assay buffer ( dotted line). 
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FIG. 7 Titration of crude Stx2 in the Stx2 binding flow cytometric assay. Crude Stx2-
positive PMN were identified by flow cytometric detection of PE-stained cells. 
The fluorescence intensities of cells from each well were normalized to the 
mean fluorescence intensity value obtained from cells incubated in an estimated 
750 ng/ml crude Stx2. The results shown are expressed as the percentage of 
PMN that are Stx2-positive (A) or as relative fluorescence intensities (B) and 
represent means of duplicate or triplicate wells for each crude Stx2 
concentration tested. Note: two granulocyte preparations were evaluated in 
assay 2 as denoted by gray and black diamonds. A titration of purified Stx2 is 
included for comparison. Error bars reflect + 1 standard deviation (percent 
Stx2+) or -1 standard deviation (relative fluorescence) of each mean. 
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Post-assay viability and PMN counts. No apparent effects of treatment on cell 
sample viability or PMN counts were noted. Pre-assay viability estimates ranged from 92% 
to 99% (median 99%). All cell samples evaluated that were incubated in either crude 
Stx2(kw) or crude Stx-negative (n = 57) had post-assay viability estimates of ~90% 
(median 99). PMN differential counts of smears prepared from samples incubated in crude 
Stx2(kw) or crude Stx-negative were normalized to pre-assay PMN counts. The median 
normalized post-assay PMN counts was 100 and ranged from 84-116 for all treatments 
evaluated (n = 56). 
Effects of incubation time and temperature on crude Stx2 binding. In cells 
incubated in crude Stx2(kw) at 4°C, the peak percentage of Stx2-positive PMN (~98%) was 
observed following 15-30 min incubations and was maintained in cells incubated in crude 
Stx2(kw) for 60 min. At 37°C, the peak percentage of Stx2-positive PMN (97%, assay 1; 
93%, assay 2) was observed following 15 min incubations in crude Stx2(kw). In assay 2, 
but not assay 1, the percentage of Stx2-positive PMN was lower in cells incubated in crude 
Stx2(kw) for 60 min (86%) than in cells incubated for 15 or 30 min. No large shifts in the 
fluorescence intensities of cell samples incubated at either 4°C or 37°C over time were 
noted (Fig. 4B and C). A minor decrease in fluorescence intensities was observed in cell 
samples incubated in crude Stx2(kw) for 60 min in assay 2 (results not shown). These 
results showed that crude Stx2(kw) binding can be detected in cell samples incubated in 
crude Stx2(kw) for as little as 15 min at either 4°C or 37°C. 
Discussion 
In this study, we established multi-color flow cytometric assays for use in functional 
studies to monitor Stx2 binding and Gb3 expression on isolated porcine peripheral blood 
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PMN. Reproducibility experiments showed no differences in Stx2 binding to PMN isolated 
from different pigs following incubation of granulocytes in either purified or crude Stx2. 
Additional experiments at 4 °C showed that the incubation step with purified Stx2 or crude 
Stx2 could be reduced from 1 h to 15 min with no apparent effects on Stx2 binding. 
The Stx2 binding flow cytometric assay requires only two incubations and one wash 
step, which minimize the number of times that cells are handled (five times) and the time 
needed to complete the assay. The assay can be completed in as little as 75 min (excluding 
the time required for flow cytometric acquisition of data) when the Stx2 incubation time at 
4 °C is decreased from 1 h to 15 min. In contrast, the use of sequential incubations of 
samples in each reagent (i.e. , Stx2, anti-Stx2, anti-rabbit antibody, PG68A, and anti-mouse 
antibody) with wash steps between each incubation may increase the number of times cells 
are handled (> 10 times) and require 24 h to complete ( excluding flow cytometric 
acquisition time). 
PMN are sensitive to ex vivo handling and multiple manipulations induce 
phenotypic and functional changes (36, 39). Multiple manipulations may make it difficult 
to discern if any changes in PMN that occur following incubation in Stx are Stx-mediated 
or are handling-mediated. The use of co-incubations of reagents did not affect background 
staining as reflected by the low percentages of PE- or FITC-positive cells identified in the 
negative controls. Similar co-incubations of primary antibodies and labeled secondary 
antibodies are reported for flow cytometric detection of leukocyte markers on bovine (22) 
and porcine (27) peripheral blood leukocytes. Thus, the protocols described in this study 
are ideal for multi-color flow cytometric analysis of porcine PMN in studies with Stx2. 
The identification of Stx binding to isolated porcine peripheral blood PMN by using 
the Stx2 binding flow cytometric assay confirms the previous report that Stx binds to 
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porcine PMN (27) and extends those findings to viable PMN. The electronic gating 
strategies used in the flow cytometric assays were based on the light scatter properties of 
porcine PMN (17) however, the exclusivity of these gates could not be tested under the 
conditions of this assay. It is possible that the PMN gate contained some eosinophils. The 
presence or absence of eosinophils in the PMN gate could not be discerned due to the lack 
of porcine eosinophil-specific reagents. Only reagents that are pan-granulocyte specific are 
presently available. 
The 50% saturating Stx2 concentration estimates ranged from 105-145 with 
purified Stx2 and 45-190 ng/ml with crude Stx2(kw). Based on these findings, Stx2 
concentrations of2:380 ng/ml are recommended for use in the binding flow cytometric 
assay. Reproducible results were obtained with cell samples incubated in Stx2 at a Stx2 
concentration that exceeded 380 ng/ml (i.e. , 750 ng/ml purified Stx2 or crude Stx2). The 
identification of Stx2-positive PMN in cell samples incubated in either of two different 
crude Stx2 preparations, but not in cells incubated in crude Stx-negative was an important 
finding. This finding showed that (i) crude Stx2 preparations are suitable alternatives to 
purified toxin for binding studies, (ii) the assay was specific for Stx2 and not other bacterial 
components and (iii) the presence of other bacterial components in crude Stx2 did not 
inhibit Stx2 binding. Although crude Stx2(kw) contained a 4-fold higher concentration of 
bacterial proteins than crude Stx2(rnhi), the Stx2 yield in crude Stx2(kw) was over 100-fold 
lower on a protein basis. When the preparations were adjusted to a common Stx2 
concentration, the adjustment of crude Stx2(kw) required a lower dilution factor than crude 
Stx2(mhi). As a result, cells incubated in crude Stx2(kw) received a higher concentration 
of bacterial proteins than did cells incubated in crude Stx2(mhi). Even with these 
differences, similar Stx2 binding results were obtained following incubation of cells in 
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either of the crude Stx2 preparations (or purified Stx2). These findings indicate that the 
EHEC ELISA estimates of Stx2 concentration, but not the estimates of protein 
concentration, are predictive of Stx2 binding. 
The Stx2 binding flow cytometric assay was developed and characterized by using 
PMN isolated from donor pigs that ranged in age from 3 months to > 1 yr old. No 
differences in Stx2 binding to isolated PMN were observed between pigs or between blood 
draws from each pig. Although neonatal pigs are used to study Stx-mediated disease (4, 5, 
7, 35), no PMN were isolated from pigs <3 months old for this study. The flow cytometric 
assays described here can be used to ascertain if Stx binds to peripheral blood PMN isolated 
from neonatal pigs and if such PMN express Gb3. 
The flow cytometric assays will be suitable for monitoring Stx binding and Gb3 
expression in functional studies with isolated porcine peripheral blood PMN and for 
determining if Stx binds to porcine peripheral blood PMN in vivo as it does to human PMN 
(31 ). The ability to use either purified Stx2 or crude Stx2, non-purified anti-Stx2 antibodies 
(antiserum), and either PE- or FITC-conjugated secondary antibodies, as well as alternative 
incubation temperatures (i.e. , 4°C or 37°C), to detect Stx binding provides flexibility in the 
choice of reagents and conditions for multi-color flow cytometric analysis for such studies. 
An advantage of using porcine PMN instead of human PMN in functional studies with Stx 
is that the relevance of in vitro findings obtained with porcine PMN can be tested using 
established porcine STEC disease models. 
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GENERAL SUMMARY AND DISCUSSION 
Shiga toxins (Stxs) are important virulence factors produced by Stx-producing 
Escherichia coli (STEC) strains and cause systemic disease in humans [reviewed in (13, 
29)] and pigs (6, 7, 11, 18, 20, 30). Vascular endothelial cells (8) and renal epithelial cells 
(12, 15) are key targets for Stx-mediated damage, but other cell types may also play roles in 
the pathogenesis of Stx-mediated disease. To elucidate what roles various cell types may 
have in Stx-mediated disease, one must first identify the cell or tissue types to which Stx 
binds. The two studies presented in this thesis focused on the development and use of in 
vitro methods to identify Stx binding sites on isolated porcine tissues and leukocytes. The 
results of these studies supported the hypothesis that porcine tissues and leukocytes contain 
Stx binding sites. 
In the first study of this thesis (Chapter 2), an immunohistochemical Stx overlay 
assay (22) was modified for use with porcine tissues to identify Stx binding sites and to 
localize the Stx receptor, Gb3. The identification of Stx binding sites in isolated porcine 
tissues and the finding that Stx binds to isolated porcine leukocytes supports the further use 
of porcine models to study STEC disease. Some of the Stx binding sites identified in 
porcine tissue sections corresponded to sites where lesions have been identified in 
experimentally STEC infected pigs (e.g., tubules, glomeruli, and vessels in kidney, and 
vessels in cerebellum) (11, 20, 30). Other Stx binding sites, namely those in liver, intestinal 
lymphoid tissues and on isolated leukocytes [alveolar macrophages, peripheral blood 
monocytes and polymorphonuclear leukocytes (PMN)] were not previously reported in pigs 
and warrant further investigation. 
The role of liver leukocytes in STEC disease is unknown, but these cells may be 
involved in Stx clearance or in the host immune response to Stx. Studies in mice indicate 
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that macrophages (2), in particular liver and splenic macrophages (19), are important for 
Stx toxicity. Interaction of tissue macrophages with Stx may induce production of 
proinflammatory mediators (24, 28, 31) that may, in turn, induce a number of downstream 
events such as the upregulation of Gb3 on vascular endothelial cells (23) and the infiltration 
of proinflammatory leukocytes (1 ). The evaluation of other leukocyte-rich porcine tissues 
that were not included in this study (e.g., spleen, peripheral lymph nodes and lung) by using 
the Stx overlay assays may result in the identification of other leukocyte types that bind Stx. 
Additional investigations are needed to determine if porcine leukocytes play a role in Stx-
mediated disease in pigs. 
The usefulness of the Stx overlay and Gb3 immunohistochemical assays were 
further demonstrated in a study by Pohlenz, et al., (20). In that study, Stx2 binding sites 
and Gb3 were localized in kidneys that were collected from STEC-inoculated piglets. The 
sites identified by using the assays (kidney tubules, glomeruli, blood vessels, and cells in 
the outer cortex) corresponded to sites where Stx-mediated lesions were observed (20). 
In humans, the risk of developing systemic STEC disease (i.e., the hemolytic uremic 
syndrome; HUS) is greatest in children age five and under and in the elderly [reviewed in 
(21)]. Age-related changes in the distribution of Gb3 and in the expression of various Gb3 
isoforms in the human kidney could affect Stx binding and may be involved in the 
susceptibility of young children and the elderly to HUS (4, 16). Neonatal (6, 7, 11, 18, 20, 
30), but not older pigs (3), develop systemic disease following experimental infection with 
human STEC strains, including STEC 0157 strains. The colonization and persistence of 
STEC O 157 strains in experimentally inoculated older pigs (2:3 months old) with an 
absence of symptoms of systemic or intestinal STEC disease (3, 5) indicate that pigs might 
undergo similar age-related changes in susceptibility to STEC disease. The Stx overlay 
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assays described in Chapter 2 will be useful for determining if age-related changes in Stx 
binding occur in porcine tissues. 
In the second study of this thesis (Chapter 3), a flow cytometric assay was 
developed and used to demonstrate Stx binding to viable porcine PMN that were isolated 
from peripheral blood. Similar Stx binding is observed with isolated human peripheral 
blood PMN (26) by using flow cytometric assays (25 , 27). We confirmed the previous 
finding that Stx binds to isolated porcine PMN (32) and extended these findings to show 
that crude Stx preparations are suitable alternatives to purified Stx for Stx binding studies. 
There are two key advantages to using crude Stx preparations. First, crude preparations can 
be readily prepared from broth cultures of STEC strains without time-consuming or 
expensive purification procedures. Large quantities of crude Stx can be obtained by scaling 
up the culture volumes. Second, crude Stx preparations contain other bacterial components 
that are likely to be present during STEC infections. The use of crude Stx preparations may 
therefore provide a more relevant representation of what host cells are exposed to during an 
STEC infection than would the use of purified Stx preparations. 
Studies with isolated human PMN (14, 17) and of HUS patients (9, 10) indicate that 
PMN play a role in Stx-mediated systemic disease. The role of peripheral blood PMN in 
naturally or experimentally acquired porcine STEC disease is unknown. The use of the 
flow cytometric Stx binding assay will facilitate studies with porcine PMN to determine if 
these cells play a role in Stx transport in pigs and if Stx induces functional effects on 
porcine PMN. A distinct advantage of using porcine PMN over human PMN for in vitro 
studies is that in vitro findings with porcine PMN can be assessed for relevance by using 
established porcine STEC infection models. The findings from such studies may lead to a 
better understanding of the pathogenesis of STEC disease in both pigs and humans. 
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APPENDIX: PUBLISHER REPRINT OF THE PAPER PRESENTED IN 
CHAPTER2 
The reprint can be found in the pocket located inside the back cover. The full 
reference for this article is as follows: Winter, K. R. K., W. C. Stoffregen, and E. A. Dean-
Nystrom. 2004. Shiga toxin binding to isolated porcine tissues and peripheral blood 
leukocytes. Infection and Immunity, Volume 72, Issue 11, pages 6680-84. 
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